Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC.
10.3779/j.issn.1009-3419.2023.101.05
- Author:
Meiyi XU
1
;
Jiawei LUO
2
;
Ruilian XU
2
Author Information
1. The Second Clinical Medical College, Jinan University, Shenzhen 518020, China.
2. Department of Oncology, Shenzhen People's Hospital, Shenzhen 518020, China.
- Publication Type:Journal Article
- Keywords:
EGFR exon 20ins mutation;
EGFR mutation;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung;
Lung Neoplasms;
ErbB Receptors;
Exons;
Mutation
- From:
Chinese Journal of Lung Cancer
2023;26(2):151-157
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer has become one of the most dangerous cancers to human health and the mortality rate is the highest among all the causes of cancer death. Non-small cell lung cancer (NSCLC) accounts for about 80%-85% of lung cancer. Chemotherapy is the main treatment for advanced NSCLC, but the 5-year survival rate is low. Epidermal growth factor receptor (EGFR) mutations are the most common driver mutations in lung cancer, but EGFR exon 20 insertions (EGFR ex20ins) mutation belongs to one of the rare mutations, accounting for about 4%-10% of overall EGFR mutations, thus around 1.8% of advanced NSCLC patients. In recent years, targeted therapies represented by EGFR tyrosine kinase inhibitors (TKIs) have become an important treatment option for patients with advanced NSCLC, however, NSCLC patients with EGFR ex20ins mutation are not sensitive to most of EGFR-TKIs treatments. Currently, some of the targeted drugs for EGFR ex20ins mutation have achieved significant efficacy, while some of them are still under clinical investigation. In this article, we will describe various treatment methods for EGFR ex20ins mutation and their efficacy.
.
